-
1
-
-
0025236913
-
-
M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Proc. Natl. Acad. Sci. U.S.A. 87 1990 1932
-
(1990)
Proc. Natl. Acad. Sci. U.S.A.
, vol.87
, pp. 1932
-
-
Herkenham, M.1
Lynn, A.B.2
Little, M.D.3
Johnson, M.R.4
Melvin, L.S.5
De Costa, B.R.6
Rice, K.C.7
-
5
-
-
60149099074
-
-
S. McGaraughty, K.L. Chu, M.J. Dart, B.B. Yao, and M.D. Meyer Neuroscience 158 2009 1652
-
(2009)
Neuroscience
, vol.158
, pp. 1652
-
-
McGaraughty, S.1
Chu, K.L.2
Dart, M.J.3
Yao, B.B.4
Meyer, M.D.5
-
6
-
-
59149090322
-
-
B.B. Yao, G. Hsieh, A.V. Daza, Y. Fan, G.K. Grayson, T.R. Garrison, O.E. Kouhen, B.A. Hooker, M. Pai, E.J. Wensink, A.K. Salyers, P. Chandran, C.Z. Zhu, C. Zhong, K. Ryther, M.E. Gallagher, C. Chin, A.E. Tovcimak, V.P. Hradil, G.B. Fox, M.J. Dart, P. Honore, and M.D. Meyer J. Pharmacol. Exp. Ther. 328 2009 141
-
(2009)
J. Pharmacol. Exp. Ther.
, vol.328
, pp. 141
-
-
Yao, B.B.1
Hsieh, G.2
Daza, A.V.3
Fan, Y.4
Grayson, G.K.5
Garrison, T.R.6
Kouhen, O.E.7
Hooker, B.A.8
Pai, M.9
Wensink, E.J.10
Salyers, A.K.11
Chandran, P.12
Zhu, C.Z.13
Zhong, C.14
Ryther, K.15
Gallagher, M.E.16
Chin, C.17
Tovcimak, A.E.18
Hradil, V.P.19
Fox, G.B.20
Dart, M.J.21
Honore, P.22
Meyer, M.D.23
more..
-
11
-
-
84859444183
-
-
Estimation of in vivo psychoactivity: In order to qualitatively estimate the level of CB1 induced CNS side effects, test compounds were dissolved in MDAA and PEG solution and intravenously injected into the tail of the ICR mice (0.1 mg/kg and 1.0 mg/kg, n = 3 each). The apparent behavior of each mouse was observed at 15 min after injection and the score (5: Tonic convulsion; 4: Catalepsy; 3: Prone position, Sedation; 2: Crawling; 1: Decrease in locomotor activity; 0: Normal) was determined. The higher the score, the more potent are the CNS side effects
-
Estimation of in vivo psychoactivity: In order to qualitatively estimate the level of CB1 induced CNS side effects, test compounds were dissolved in MDAA and PEG solution and intravenously injected into the tail of the ICR mice (0.1 mg/kg and 1.0 mg/kg, n = 3 each). The apparent behavior of each mouse was observed at 15 min after injection and the score (5: Tonic convulsion; 4: Catalepsy; 3: Prone position, Sedation; 2: Crawling; 1: Decrease in locomotor activity; 0: Normal) was determined. The higher the score, the more potent are the CNS side effects.
-
-
-
-
12
-
-
0032819443
-
-
F. Bondavalli, O. Bruno, E.L. Presti, G. Menozzi, and L. Mosti Synthesis 7 1999 1169 1174
-
(1999)
Synthesis
, vol.7
, pp. 1169-1174
-
-
Bondavalli, F.1
Bruno, O.2
Presti, E.L.3
Menozzi, G.4
Mosti, L.5
-
13
-
-
84859440519
-
-
3H]-CP55940 for each membrane fraction were determined by Scatchard plot analysis
-
3H]-CP55940 for each membrane fraction were determined by Scatchard plot analysis.
-
-
-
-
14
-
-
84859446152
-
-
Cyclic AMP assay method: The CHO cells expressing hCB1 or hCB2 were seeded into 24-well plates. The cells were incubated at 37 °C for 20 min with compounds in the cAMP assay buffer (Hanks' solution with 20 mM HEPES, 0.1 mM IBMX, 0.2 mM Ro20-1724, 0.1% BSA). The cells were stimulated with 4 μM forskolin at 37 °C for 25 min (hCB1 cells) or 45 min (hCB2 cells). The cAMP concentrations in the cells were measured using cAMP kits (CIS Bio International)
-
Cyclic AMP assay method: The CHO cells expressing hCB1 or hCB2 were seeded into 24-well plates. The cells were incubated at 37 °C for 20 min with compounds in the cAMP assay buffer (Hanks' solution with 20 mM HEPES, 0.1 mM IBMX, 0.2 mM Ro20-1724, 0.1% BSA). The cells were stimulated with 4 μM forskolin at 37 °C for 25 min (hCB1 cells) or 45 min (hCB2 cells). The cAMP concentrations in the cells were measured using cAMP kits (CIS Bio International).
-
-
-
-
15
-
-
84859444184
-
-
In vivo assay (pruritic model): Crj:CD-1 (ICR) (Japan Charles River Lab.) mice were used for the scratching test to investigate the antipruritic effect. Test compounds were dissolved in acetone (Sigma). Compound 48/80 as a pruritogen dissolved at 75 μg/ml in isotonic saline (Otsuka Pharma.). Test compounds were administered as forced oral dosages to mice. After 1 h, 40 μl of pruritogen was injected intradermally into the back of mice. Thereafter, their behavior was videotaped to count the scratching behavior for 30 min. The % inhibition value was calculated with the equation: % inhibition = (B-A) - (C-A)/(B-A/100); scratching of control (n = 29) as A, scratching of vehicle (n = 6) as B, scratching of test mice (n = 6) as C
-
In vivo assay (pruritic model): Crj:CD-1 (ICR) (Japan Charles River Lab.) mice were used for the scratching test to investigate the antipruritic effect. Test compounds were dissolved in acetone (Sigma). Compound 48/80 as a pruritogen dissolved at 75 μg/ml in isotonic saline (Otsuka Pharma.). Test compounds were administered as forced oral dosages to mice. After 1 h, 40 μl of pruritogen was injected intradermally into the back of mice. Thereafter, their behavior was videotaped to count the scratching behavior for 30 min. The % inhibition value was calculated with the equation: % inhibition = (B-A) - (C-A)/(B-A/100); scratching of control (n = 29) as A, scratching of vehicle (n = 6) as B, scratching of test mice (n = 6) as C.
-
-
-
|